Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ENDOCRINE THERAPY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 378 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Taneja, SS; Ha, S; Garabedian, MJ
      Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression

      JOURNAL OF CELLULAR BIOCHEMISTRY
    2. Vantaux, P; Schneider, P; Le Coz, S; Villers, A
      Prostate cancer presenting in the form of disseminated intravascular coagulation

      PROGRES EN UROLOGIE
    3. Bange, J; Zwick, E; Ullrich, A
      Molecular targets for breast cancer therapy and prevention

      NATURE MEDICINE
    4. Hayes, DF; Yamauchi, H; Broadwater, G; Cirrincione, CT; Rodrigue, SP; Berry, DA; Younger, J; Panasci, LL; Millard, F; Duggan, DB; Norton, L; Henderson, IC
      Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662

      CLINICAL CANCER RESEARCH
    5. Bagatell, R; Khan, O; Paine-Murrieta, G; Taylor, CW; Akinaga, S; Whitesell, L
      Destabilization of steroid receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer

      CLINICAL CANCER RESEARCH
    6. Suo, ZH; Yang, HH; Mei, Q; Skovlund, E; Cui, JG; Nesland, JM
      Type 1 protein tyrosine kinases in Chinese breast carcinomas - A clinicopathologic study

      INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
    7. Ferrero-Pous, M; Trassard, M; Le Doussal, V; Hacene, K; Tubiana-Hulin, M; Spyratos, F
      Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients

      APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
    8. Danova, M; Porta, C; Ferrari, S; Riccardi, A
      Strategies of medical treatment for metastatic breast cancer

      INTERNATIONAL JOURNAL OF ONCOLOGY
    9. Maltais, R; Luu-The, V; Poirier, D
      Parallel solid-phase synthesis of 3 beta-peptido-3 alpha-hydroxy-5 alpha androstan-17-one derivatives for inhibition of type 3 17 beta-hydroxysteroiddehydrogenase

      BIOORGANIC & MEDICINAL CHEMISTRY
    10. Bell, R
      Duration of therapy in metastatic breast cancer: management using Herceptin (R)

      ANTI-CANCER DRUGS
    11. Bieche, I; Parfait, B; Nogues, C; Andrieu, C; Vidaud, D; Spyratos, F; Lidereau, R; Vidaud, M
      The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients

      ONCOGENE
    12. Carlini, P; Frassoldati, A; De Marco, S; Casali, A; Ruggeri, EM; Nardi, M; Papaldo, P; Fabi, A; Paoloni, F; Cognetti, F
      Formestane, a steroidal aromatase inhibitor after failure of non-steroidalaromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?

      ANNALS OF ONCOLOGY
    13. Piccart, MJ
      Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

      ANNALS OF ONCOLOGY
    14. Tanaka, M; Suzuki, Y; Takaoka, K; Suzuki, N; Murakami, S; Matsuzaki, O; Shimazaki, J
      Progression of prostate cancer to neuroendocrine cell tumor

      INTERNATIONAL JOURNAL OF UROLOGY
    15. Furuya, Y; Akakura, K; Tanaka, M; Ichikawa, T; Igarashi, T; Murakami, S; Ito, H
      Endocrine therapy for recurrence after definitive radiotherapy in patientswith prostate cancer

      INTERNATIONAL JOURNAL OF UROLOGY
    16. Imamoto, T; Suzuki, H; Akakura, K; Komiya, A; Nakamachi, H; Ichikawa, T; Igarashi, T; Ito, H
      Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

      ENDOCRINE JOURNAL
    17. Onozawa, M; Fukuda, K; Watanabe, M; Ohtani, M; Akaza, H; Sugimura, T; Wakabayashi, K
      Detection and cloning of a protein recognized by anti-human prostate-specific antigen (PSA) antibody in the rat ventral prostate

      JAPANESE JOURNAL OF CANCER RESEARCH
    18. Buzdar, A; Douma, J; Davidson, N; Elledge, R; Morgan, M; Smith, R; Porter, L; Nabholtz, J; Xiang, X; Brady, C
      Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

      JOURNAL OF CLINICAL ONCOLOGY
    19. Knoop, AS; Bentzen, SM; Nielsen, MM; Rasmussen, BB; Rose, C
      Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    20. Mouridsen, H; Gershanovich, M; Sun, Y; Perez-Carrion, R; Boni, C; Monnier, A; Apffelstaedt, J; Smith, R; Sleeboom, HP; Janicke, F; Pluzanska, A; Dank, M; Becquart, D; Bapsy, PP; Salminen, E; Snyder, R; Lassus, M; Verbeek, JA; Staffler, B; Chaudri-Ross, HA; Dugan, M
      Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group

      JOURNAL OF CLINICAL ONCOLOGY
    21. Barnes, DM; Hanby, AM
      Oestrogen and progesterone receptors in breast cancer: past, present and future

      HISTOPATHOLOGY
    22. Bieche, I; Onody, P; Lerebours, F; Tozlu, S; Hacene, K; Andrieu, C; Vidaud, M; Tubiana-Hulin, M; Spyratos, F; Lidereau, R
      ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma

      CANCER LETTERS
    23. Omoto, Y; Inoue, S; Ogawa, S; Toyama, T; Yamashita, H; Muramatsu, M; Kobayashi, S; Iwase, H
      Clinical value of the wild-type estrogen receptor beta expression in breast cancer

      CANCER LETTERS
    24. Van Poppel, H
      Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out

      EUROPEAN UROLOGY
    25. Rocco, F; Gadda, F; Rocco, B; Acquati, P; Grisotto, M
      Hormone therapy in prostate cancer

      TUMORI
    26. Lonning, PE; Taylor, PD; Anker, G; Iddon, J; Wie, L; Jorgensen, LM; Mella, O; Howell, A
      High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

      BREAST CANCER RESEARCH AND TREATMENT
    27. Kenny, FS; Willsher, PC; Gee, JMW; Nicholson, RI; Pinder, SE; Ellis, IO; Robertson, JFR
      Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    28. Cheung, KL; Nicholson, RI; Blamey, RW; Robertson, JFR
      Selection of primary breast cancer patients for adjuvant endocrine therapy- is oestrogen receptor alone adequate?

      BREAST CANCER RESEARCH AND TREATMENT
    29. Oyama, N; Akino, H; Suzuki, Y; Kanamaru, H; Ishida, H; Tanase, K; Sadato, N; Yonekura, Y; Okada, K
      FDG PET for evaluating the change of glucose metabolism in prostate cancerafter androgen ablation

      NUCLEAR MEDICINE COMMUNICATIONS
    30. Dees, EC; Davidson, NE
      Ovarian ablation as adjuvant therapy for breast cancer

      SEMINARS IN ONCOLOGY
    31. Grossfeld, GD; Small, EJ; Lubeck, DP; Latini, D; Broering, JM; Carroll, PR
      Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

      UROLOGY
    32. Grossfeld, GD; Chaudhary, UB; Reese, DM; Carroll, PR; Small, EJ
      Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer

      UROLOGY
    33. Thike, AA; Chng, MJ; Fook-Chung, S; Tan, PH
      Immunohistochemical expression of hormone receptors in invasive breast carcinoma: Correlation of results of H-score with pathological parameters

      PATHOLOGY
    34. Piccart, M; Lohrisch, C; Di Leo, A; Larsimont, D
      The predictive value of HER2 in breast cancer

      ONCOLOGY
    35. Vyzula, R; Zaloudik, J; Dusek, L; Vermousek, I
      Seasonal variation in estrogen and progesterone receptor levels in breast cancer - a factor in data interpretation

      NEOPLASMA
    36. Donovan, JCH; Milic, A; Slingerland, JM
      Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells

      JOURNAL OF BIOLOGICAL CHEMISTRY
    37. Gee, JMW; Robertson, JFR; Ellis, IO; Nicholson, RI
      Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

      INTERNATIONAL JOURNAL OF CANCER
    38. McClelland, RA; Barrow, D; Madden, TA; Dutkowski, CM; Pamment, J; Knowlden, JM; Gee, JMW; Nicholson, RI
      Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)

      ENDOCRINOLOGY
    39. Dorssers, LCJ; van der Flier, S; Brinkman, A; van Agthoven, T; Veldscholte, J; Berns, EMJJ; Klijn, JGM; Beex, LVAM; Foekens, JA
      Tamoxifen resistance in breast cancer - Elucidating mechanisms

      DRUGS
    40. Robertson, JF; Nicholson, RI; Bundred, NJ; Anderson, E; Rayter, Z; Dowsett, M; Fox, JN; Gee, JMW; Webster, A; Wakeling, AE; Morris, C; Dixon, M
      Comparison of the short-term biological effects of 7 alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer

      CANCER RESEARCH
    41. Bonneterre, J; Buzdar, A; Nabholtz, JMA; Robertson, JFR; Thurlimann, B; von Euler, M; Sahmoud, T; Webster, A; Steinberg, M
      Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma - Results of two randomized trials designed for combined analysis

      CANCER
    42. Focan, C; Beauduin, M; Salamon, E; de Greve, J; de Wasch, G; Lobelle, JP; Majois, F; Tagnon, A; Tytgat, J; van Belle, S; Vandervellen, R; Vindevoghel, A
      Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial

      BRITISH JOURNAL OF CANCER
    43. Oliver, RTD; Farrugia, D; Ansell, W; Willams, G; Chinegwundoh, F
      Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients

      PROSTATE CANCER AND PROSTATIC DISEASES
    44. Ciocca, DR; Elledge, R
      Molecular markers for predicting response to tamoxifen in breast cancer patients

      ENDOCRINE
    45. Eguchi, H; Suga, K; Saji, H; Toi, M; Nakachi, K; Hayashi, SI
      Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene

      CELL DEATH AND DIFFERENTIATION
    46. Bostwick, DG
      Immunohistochemical changes in prostate cancer after androgen deprivation therapy

      MOLECULAR UROLOGY
    47. Bruchovsky, N; Klotz, LH; Sadar, M; Crook, JM; Hoffart, D; Godwin, L; Warkentin, M; Gleave, ME; Goldenberg, SL
      Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations

      MOLECULAR UROLOGY
    48. Moul, JW
      Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy

      MOLECULAR UROLOGY
    49. Chang, J; Powles, TJ; Allred, DC; Ashley, SE; Makris, A; Gregory, RK; Osborne, CK; Dowsett, M
      Prediction of clinical outcome from primary tamosifen by expression of biologic markers in breast cancer patients

      CLINICAL CANCER RESEARCH
    50. Buzdar, AU
      Tamoxifen's clinical applications - Old and new

      ARCHIVES OF FAMILY MEDICINE
    51. Culig, Z; Hobisch, A; Bartsch, G; Klocker, H
      Expression and function of androgen receptor in carcinoma of the prostate

      MICROSCOPY RESEARCH AND TECHNIQUE
    52. Lonning, PE
      Clinico-pharmacological aspects of different hormone treatments

      EUROPEAN JOURNAL OF CANCER
    53. Buzdar, A
      Exemestane in advanced breast cancer

      ANTI-CANCER DRUGS
    54. Eder, IE; Culig, Z; Ramoner, R; Thurnher, M; Putz, T; Nessler-Menardi, C; Tiefenthaler, M; Bartsch, G; Klocker, H
      Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

      CANCER GENE THERAPY
    55. Stal, O; Borg, A; Ferno, M; Kallstrom, AC; Malmstrom, P; Nordenskjold, B
      ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

      ANNALS OF ONCOLOGY
    56. Kasimis, B; Wilding, G; Kreis, W; Feuerman, M; Chang, V; Hwang, S; Steafather, H; Cogswell, J; Rae, C; Blumenfrucht, M
      Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer

      CANCER INVESTIGATION
    57. Kapur, S
      A medical hypothesis: Phosphorus balance and prostate cancer

      CANCER INVESTIGATION
    58. Bonneterre, J; Thurlimann, B; Robertson, JFR; Krzakowski, M; Mauriac, L; Koralewski, P; Vergote, I; Webster, A; Steinberg, M; von Euler, M
      Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study

      JOURNAL OF CLINICAL ONCOLOGY
    59. Nabholtz, JM; Buzdar, A; Pollak, M; Harwin, W; Burton, G; Mangalik, A; Steinberg, M; Webster, A; von Euler, M
      Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial

      JOURNAL OF CLINICAL ONCOLOGY
    60. Berry, DA; Muss, HB; Thor, AD; Dressler, L; Liu, ET; Broadwater, G; Budman, DR; Henderson, IC; Barcos, M; Hayes, D; Norton, L
      HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    61. Sledge, GW; Hu, P; Falkson, G; Tormey, D; Abeloff, M
      Comparison of chemotherapy with chemohormonal therapy as first-line therapy-for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study

      JOURNAL OF CLINICAL ONCOLOGY
    62. Coradini, D; Daidone, MG; Boracchi, P; Biganzoli, E; Oriana, S; Bresciani, G; Pellizzaro, C; Tomasic, G; Di Fronzo, G; Marubini, E
      Time-dependent relevance of steroid receptors in breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    63. Sciarra, A; Di Chiro, C; Di Silverio, F
      Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer

      WORLD JOURNAL OF UROLOGY
    64. Stockler, M; Wilcken, NRC; Ghersi, D; Simes, RJ
      Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

      CANCER TREATMENT REVIEWS
    65. Kollerman, J; Feek, U; Muller, H; Kaulfuss, U; Oehler, U; Helpap, B; Kollermann, MW
      Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma

      EUROPEAN UROLOGY
    66. Ather, MH; Abbas, F
      Prognostic significance of neuroendocrine differentiation in prostate cancer

      EUROPEAN UROLOGY
    67. Bouchot, O; Lenormand, L; Karam, G; Prunet, D; Gaschignard, N; Malinovsky, JM; Buzelin, JM
      Intermittent androgen suppression in the treatment of metastatic prostate cancer

      EUROPEAN UROLOGY
    68. Gyftopoulos, K; Sotiropoulou, G; Varakis, I; Barbalias, GA
      Cellular distribution of retinoic acid receptor-alpha in benign hyperplastic and malignant human prostates: Comparison with androgen, estrogen and progesterone receptor status

      EUROPEAN UROLOGY
    69. Matsuura, H; Hayashi, N; Kawamura, J; Shiraishi, T; Yatani, R
      Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation

      EUROPEAN UROLOGY
    70. Higa, GM
      Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors

      PHARMACOTHERAPY
    71. Bonkhoff, H; Fixemer, T; Hunsicker, I; Remberger, K
      Estrogen receptor gene expression and its relation to the estrogen-inducible HSP27 heat shock protein in hormone refractory prostate cancer

      PROSTATE
    72. Vorgias, G; Koukouras, D; Tzoracoeleftherakis, E; Paleogianni, V; Androulakis, J
      Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen

      ANTICANCER RESEARCH
    73. Helal, TE; Khalifa, A; Kamel, AS
      Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt

      ANTICANCER RESEARCH
    74. Nicholson, BP
      Ongoing and planned trials of hormonal therapy and trastuzumab

      SEMINARS IN ONCOLOGY
    75. Mass, R
      The role of HER-2 expression in predicting response to therapy in breast cancer

      SEMINARS IN ONCOLOGY
    76. Hobisch, A; Hoffmann, J; Lambrinidis, L; Eder, IE; Bartsch, G; Klocker, H; Culig, Z
      Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model

      UROLOGIA INTERNATIONALIS
    77. Rost, NS; Murphy, K; Hafer, L; Pavao, M; Traish, AM
      Immunochemical analyses of estrogen receptors in human breast tumors by a novel monoclonal estrogen receptor antibody (EVG F9)

      STEROIDS
    78. Kurebayashi, J; Sonoo, H; Inaji, H; Nishimura, R; Iino, Y; Toi, M; Kobayashi, S; Saeki, T
      Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies

      ONCOLOGY
    79. deFazio, A; Chiew, YE; Sini, RL; Janes, PW; Sutherland, RL
      Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines

      INTERNATIONAL JOURNAL OF CANCER
    80. Konecny, G; Pegram, M; Untch, M; Thomssen, C; Janicke, F; Hepp, H; Slamon, DJ
      HER-2/neu as a predictive marker in breast cancer

      GEBURTSHILFE UND FRAUENHEILKUNDE
    81. Jongsma, J; Oomen, MH; Noordzij, MA; Van Weerden, WM; Martens, GJM; van der Kwast, TH; Schroder, FH; van Steenbrugge, GJ
      Androgen deprivation of the prohormone convertase-310 human prostate cancer model system induces neuroendocrine differentiation

      CANCER RESEARCH
    82. Kurokawa, H; Lenferink, AEG; Simpson, JF; Pisacane, PI; Sliwkowski, MX; Forbes, JT; Arteaga, CL
      Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-ovorexpresessed tamoxifen-resistant breast cancer cells

      CANCER RESEARCH
    83. Anderson, WF; Reeves, JE; Elias, A; Berkel, HJ
      Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic

      CANCER
    84. Mauriac, L; Blanc-Vincent, MP; Luporsi, E; Cutuli, B; Fourquet, A; Garbay, JR; Giard, S; Spyratos, F; Zafrani, B; Dilhuydy, JM
      Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer

      BULLETIN DU CANCER
    85. Kerbrat, P; Lefeuvre, C
      Aromatase inhibitors: a review of clinical trials

      BULLETIN DU CANCER
    86. van der Flier, S; Brinkman, A; Look, MP; Kok, EM; Meijer-van Gelder, ME; Klijn, JGM; Dorssers, LCJ; Foekens, JA
      Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    87. Brasso, K; Friis, S; Juel, K; Jorgensen, T; Iversen, P
      Morbidity in patients with clinically localized prostate cancer managed with non-curative intent. A population-based case-control study

      PROSTATE CANCER AND PROSTATIC DISEASES
    88. Goktas, S; Ziada, A; Crawford, ED
      Combined androgen blockade for advanced prostatic carcinoma

      PROSTATE CANCER AND PROSTATIC DISEASES
    89. Mottet, N; Costa, P; Navratil, H
      Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study

      PROSTATE CANCER AND PROSTATIC DISEASES
    90. Ziada, AM; Crawford, ED
      Advanced prostate cancer

      PROSTATE CANCER AND PROSTATIC DISEASES
    91. Duffy, MJ
      Prognostic and predictive markers in cancer

      JOURNAL OF CLINICAL LIGAND ASSAY
    92. Davies, EL; Gee, JMW; Cochrane, RA; Jiang, WG; Sharma, AK; Nicholson, RI; Mansel, RE
      The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer

      EUROPEAN JOURNAL OF CANCER
    93. Robertson, JFR; Willsher, PC; Winterbottom, L; Blamey, RW; Thorpe, S
      Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer

      EUROPEAN JOURNAL OF CANCER
    94. Andersson, M; Kamby, C; Jensen, MB; Mouridsen, H; Ejlertsen, B; Dombernowsky, P; Rose, C; Cold, S; Overgaard, M; Andersen, J; Kjaer, M
      Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial

      EUROPEAN JOURNAL OF CANCER
    95. Andersson, M; Madsen, EL; Overgaard, M; Rose, C; Dombernowsky, P; Mouridsen, HT
      Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group

      EUROPEAN JOURNAL OF CANCER
    96. Robertson, JFR; Jaeger, W; Syzmendera, JJ; Selby, C; Coleman, R; Howell, A; Winstanley, J; Jonssen, PE; Bombardieri, E; Sainsbury, JRC; Gronberg, H; Kumpulainen, E; Blamey, RW
      The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

      EUROPEAN JOURNAL OF CANCER
    97. Gadducci, A; Genazzani, AR
      Endocrine therapy for gynecological cancer

      GYNECOLOGICAL ENDOCRINOLOGY
    98. Ogasawara, Y; Doihara, H; Shiroma, K; Kanaya, Y; Shimizu, N
      Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted innude mice

      SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY
    99. Homma, Y; Akaza, H; Okada, K; Yokoyama, M; Moriyama, N; Usami, M; Hirao, Y; Tsushima, T; Sakamoto, A; Ohashi, Y; Aso, Y
      Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation

      INTERNATIONAL JOURNAL OF UROLOGY
    100. Furuya, Y; Akakura, K; Akimoto, S; Inomiya, H; Ito, H
      Pattern of progression and survival in hormonally treated metastatic prostate cancer

      INTERNATIONAL JOURNAL OF UROLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 18:18:18